The results of this randomized, double-blind, placebo-controlled, forced-do
se titration study in a diverse population of hypertensive patients in the
US indicate that candesartan cilexetil has clinically meaningful dose-relat
ed blood pressure-lowering effects and that maximum blood pressure reductio
n is achieved with doses of 16 and 32 mg given once daily. This study confi
rms that candesartan cilexetil is a highly effective antihypertensive agent
with an excellent tolerability and safety profile, without dose-related ad
verse effects.